European Journal of Dermatology

, Volume 27, Issue 4, pp 382–385 | Cite as

Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study

  • Francesco Drago
  • Giulia Ciccarese
  • Ludovica Cogorno
  • Camillo Calvi
  • Luigina A. Marsano
  • Aurora Parodi
Therapy
  • 9 Downloads

Abstract

Background

Nicotinamide is the precursor of nicotinamide adenine dinucleotide (NAD+), an essential cofactor for adenosine triphosphate (ATP) production. It has recently been reported to be effective in reducing the rates of new non-melanoma skin cancers (NMSCs) and actinic keratosis (AKs).

Objectives

We studied the efficacy of oral nicotinamide as treatment for AKs in transplant recipients.

Materials & methods

We recruited 38 transplant (eight liver and 30 kidney) patients with single or multiple AKs. Nineteen patients were randomly assigned to Group 1 and took nicotinamide 500 mg/daily (cases); the other 19 patients were randomly assigned to Group 2 without nicotinamide (controls). At base-line, AKs were identified, measured, and photographed for follow-up. Five patients underwent an AK biopsy for histopathology. Statistical analyses were performed using the Student t test.

Results

At baseline, no statistically significant differences were observed regarding AK size between the two groups. After six months, among the cases, AKs had significantly decreased in size in 18/19 patients (88%). Among these 18 patients, seven patients (42%) had shown complete clinical regression and no patient developed new AKs. Conversely, among the controls, 91% showed an increase in AK size and/or developed new AKs. Seven pre-existing AKs progressed to squamous-cell carcinoma.

Conclusion

Nicotinamide appears to be effective in preventing and treating AKs, although the mechanisms are still unclear. Further studies with a larger sample of organ transplant recipients and a longer follow-up period are needed to further support our conclusions.

Key words

non-melanoma skin cancer squamous-cell carcinoma nicotinamide transplant recipients actinic keratosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids 2010; 2010.Google Scholar
  2. 2.
    Surjana D, Halliday GM, Martin AJ, et al. Oral Nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 2012; 132: 1497–500.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen AC, Damian DL. Nicotinamide and the skin. Australas J Dermatol 2014; 55: 169–75.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373: 1618–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol 2013; 68: S2–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146: 1–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res 2005; 571: 107–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Lindelöf B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5, 356 patients following organ transplantation. Br J Dermatol 2000; 143: 513–9.PubMedGoogle Scholar
  9. 9.
    Kempf W, Mertz KD, Hofbauer GF, et al. Skin cancer in organ transplant recipients. Pathobiology 2013; 80: 302–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Poon TS, Barnetson RS, Halliday GM. Prevention of immunosuppression by sunscreens in humans is unrelated to protection from erythema and dependent on protection from ultraviolet A in the face of constant ultraviolet B protection. J Invest Dermatol 2003; 121: 184–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Niren N. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis 2006; 11: 11–6.Google Scholar
  12. 12.
    Gensler HL, Williams T, Huang AC, Jacobsen EL. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 1999; 34: 36–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis 2009; 30: 101–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Moloney FJ, Vestergaard ME, Radojkovic BL, Damian DL. Randomised, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol 2010; 162: 1138–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Park J, Halliday GM, Surjana D, et al. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol 2010; 86: 942–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Gero D, Szabo C. Poly (APD-ribose) polymerase: a new therapeutic target? Curr Opin Anaesthesiol 2008; 21: 111–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Jacobson EL, Giacomoni PU, Roberts MJ, Wondrak GT, Jacobson MK. Optimizing the energy status of skin cells during solar radiation. J Photochem Photobiol B 2001; 63: 141–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Boyonoski AC, Gallacher LM, ApSimon MM, et al. Niacin deficiency increases the sensitivity of rats to the short and long term effects of ethylnitrosourea treatment. Mol Cell Biol 1999; 193: 83–7.Google Scholar
  19. 19.
    Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther 2009; 8: 725–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Drago F, Ciccarese G, Parodi A. Nicotinamide for skin-cancer chemoprevention. N Engl J Med 2016; 374: 789–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen AC, Martin AJ, Dalziell RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol 2016; 75: 1073–5.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2017

Authors and Affiliations

  • Francesco Drago
    • 1
  • Giulia Ciccarese
    • 1
  • Ludovica Cogorno
    • 1
  • Camillo Calvi
    • 1
  • Luigina A. Marsano
    • 1
  • Aurora Parodi
    • 1
  1. 1.Department of DermatologyIRCCS AOU San Martino ISTGenoaItaly

Personalised recommendations